2nd Annual Dermatology Drug Development Summit
In-Person Event
Nov 27 - 29, 2018
Boston, Massachusetts, USA
OVERVIEW
2nd Annual Dermatology Drug Development Summit is organized by Hanson Wade and will be held from Nov 27 - 29, 2018 at Hyatt Regency Boston, Boston, Massachusetts, United States of America.
Conference Description :
The dermatology space continues to strive in therapeutic innovation. There’s been a transformative evolution in the understanding of the pathophysiology of skin diseases, and in the available treatment options for chronic, moderate to severe dermatological conditions that affect lives of millions of patients worldwide.
The 2nd annual Dermatology Drug Development Summit provides a unique forum for industry leaders to take advantage of this tremendous environment of opportunity driven by huge investments to innovate and bring better and more efficient drugs to market, for the treatment of high unmet need.
Leading organizations and experts in this space will share their exclusive insight in an end-to-end discussion sharing pharmaceutical best practice and the latest case-studies on the development and bringing to market of new and innovative dermatological drugs.
Join them to collaboratively tackle specific challenges you face in developing these drugs - from strategic concerns, to discovery, preclinical activities, formulation and delivery strategies, biologic therapies, clinical development, regulatory and commercial hurdles - and uncover the details behind the latest developments in this space.
Conference Highlights :
• LEO Pharma A/S and Sanofi explore how to truly implement precision medicine approaches in dermatology drug development.
• Dermira share their experience on how to derisk topical product development.
• Concert Pharmaceuticals and Sienna Biopharmaceuticals reveal more about the latest clinical data on their JAK Inhibitor candidates targeting alopecia areata, and atopic dermatitis and pruritus, respectively.
• Almirall address the importance of external innovation as a key factor in the sustainability of dermatology R&D.
• Galderma tackle the changing market dynamics, and the reimbursement and market access hurdles in dermatology.
• Glenmark Pharmaceuticals discuss their latest results with a novel OX40 antagonistic mAb targeting atopic dermatitis.
• Cara Therapeutics Inc. analyze how to achieve clinically meaningful endpoints in itch, and the validation of Patient-Reported Outcomes.
• Realm Therapeutics Inc. share their views on how to deal with clinical and regulatory challenges in acne clinical development.
• Incyte Corporation explore integrative preclinical research strategies to identify new therapeutic opportunities in dermatology.
• LEO Innovation Lab focus on the growing possibilities of digitization in dermatology R&D including real-world evidence, digital tools and telemedicine.
Additional details will be posted as soon as they are available.
Conference Description :
The dermatology space continues to strive in therapeutic innovation. There’s been a transformative evolution in the understanding of the pathophysiology of skin diseases, and in the available treatment options for chronic, moderate to severe dermatological conditions that affect lives of millions of patients worldwide.
The 2nd annual Dermatology Drug Development Summit provides a unique forum for industry leaders to take advantage of this tremendous environment of opportunity driven by huge investments to innovate and bring better and more efficient drugs to market, for the treatment of high unmet need.
Leading organizations and experts in this space will share their exclusive insight in an end-to-end discussion sharing pharmaceutical best practice and the latest case-studies on the development and bringing to market of new and innovative dermatological drugs.
Join them to collaboratively tackle specific challenges you face in developing these drugs - from strategic concerns, to discovery, preclinical activities, formulation and delivery strategies, biologic therapies, clinical development, regulatory and commercial hurdles - and uncover the details behind the latest developments in this space.
Conference Highlights :
• LEO Pharma A/S and Sanofi explore how to truly implement precision medicine approaches in dermatology drug development.
• Dermira share their experience on how to derisk topical product development.
• Concert Pharmaceuticals and Sienna Biopharmaceuticals reveal more about the latest clinical data on their JAK Inhibitor candidates targeting alopecia areata, and atopic dermatitis and pruritus, respectively.
• Almirall address the importance of external innovation as a key factor in the sustainability of dermatology R&D.
• Galderma tackle the changing market dynamics, and the reimbursement and market access hurdles in dermatology.
• Glenmark Pharmaceuticals discuss their latest results with a novel OX40 antagonistic mAb targeting atopic dermatitis.
• Cara Therapeutics Inc. analyze how to achieve clinically meaningful endpoints in itch, and the validation of Patient-Reported Outcomes.
• Realm Therapeutics Inc. share their views on how to deal with clinical and regulatory challenges in acne clinical development.
• Incyte Corporation explore integrative preclinical research strategies to identify new therapeutic opportunities in dermatology.
• LEO Innovation Lab focus on the growing possibilities of digitization in dermatology R&D including real-world evidence, digital tools and telemedicine.
Additional details will be posted as soon as they are available.
KEY DATES
27 Nov, 2018
Event Start Date
29 Nov, 2018
Event End Date
SPECIALITIES
DermatologyPharmacy and MedicineSUGGESTED HOTELS
CONFERENCE VENUE
Hyatt Regency BostonRELATED CONFERENCES & LIVE WEBINARS
Quick Links